Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 0877 • ACR Convergence 2020
Improvements in Global Functioning and Health-related Quality of Life and Their Association with Disease Activity and Functional Improvement in Patients with Active Ankylosing Spondylitis Treated with Upadacitinib
Uta Kiltz¹, Joachim Sieper², Atul Deodhar³, Patrick Zueger⁴, In-Ho Song⁴, Naijun Chen⁴ and Désirée van der Heijde⁵, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr-University Bochum, Herne, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Oregon Health & Science University, Portland, OR, ⁴AbbVie Inc., North Chicago, IL, ⁵Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Upadacitinib (UPA) has been shown to be effective and well tolerated in patients with active ankylosing spondylitis (AS) [1]. However, improvements in global functioning…
Abstract Number: 1316 • ACR Convergence 2020
Patient Perceptions of Fibromyalgia Symptoms and the Overlap with Axial Spondyloarthritis
Kelly Gavigan¹, William Nowell², Regan Reynolds¹, Laura Stradford¹, Jeffrey R Curtis³ and Alexis Ogdie⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Global Healthy Living Foundation, New York City, NY, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: In clinical practice, it is often challenging to distinguish fibromyalgia syndrome (FMS) from axial spondyloarthritis (axSpA), which includes ankylosing spondylitis and non-radiographic axSpA. Early stages…
Abstract Number: 1366 • ACR Convergence 2020
Secukinumab Improved Signs and Symptoms in Patients with Non-radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Stratified by Baseline Objective Signs of Inflammation
Juergen Braun¹, Ricardo Blanco², Helena Marzo-Ortega³, Lianne Gensler⁴, Filip Van den Bosch⁵, Hideto Kameda⁶, Denis Poddubnyy⁷, Marleen van de Sande⁸, Anna Wiksten⁹, Brian Porter¹⁰, Santiago Moreno⁹, Abhijit Shete⁹, Hanno Richards⁹, Sibylle Haemmerle⁹ and Atul Deodhar¹¹, ¹Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, 44649 Herne, Germany, ²Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ³The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ⁴University of California San Francisco, San Francisco, CA, ⁵Ghent University Hospital, Ghent, Belgium, ⁶Toho University, Tokyo, Japan, ⁷Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁸Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Oregon Health & Science University, Portland, OR
Background/Purpose: Active non-radiographic axial spondyloarthritis (nr-axSpA) is often determined on the basis of objective signs of inflammation (elevated C-reactive protein [CRP] and/or evidence of sacroiliitis…
Abstract Number: 1872 • ACR Convergence 2020
Relative Associations of Sociodemographic, Clinical and HLA-B Alleles with Enthesitis and Peripheral Arthritis in Patients with Ankylosing Spondylitis
Benjamin Naovarat¹, Lianne Gensler², Michael Ward³, Mark Hwang⁴, Matthew Brown⁵, Amirali Tahanan⁶, Mohammad Rahbar⁶, Mariko Ishimori⁷, Michael Weisman⁸ and John Reveille⁹, ¹The University of Texas McGovern Medical School, Houston, TX, ²University of California San Francisco, San Francisco, CA, ³National Institutes of Health, Bethesda, MD, ⁴McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ⁵Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁶McGovern Medical School at UTHealth, Houston, ⁷Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Department of Internal Medicine, University of Texas, Houston, TX
Background/Purpose: Previous studies from Latin America have shown an association with peripheral arthritis in patients with spondyloarthritis with HLA-B*15 (as opposed to HLA-B27). We aimed…
Abstract Number: 1898 • ACR Convergence 2020
Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors in the Treatment of Axial Spondyloarthritis
Loïc Choquette Sauvageau¹, Denis Choquette², Louis Bessette³, Isabelle Ferdinand¹, Boulos Haraoui⁴, Frédéric Massicotte¹, Jean-Pierre Pelletier², Jean-Pierre Raynauld², Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Édith Villeneuve¹ and Louis Coupal¹, ¹Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ²Institut de Rhumatologie de Montréal, Montreal, Canada, ³Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁴Rheumatology Institute of Montréal, Montreal, Canada
Background/Purpose: Studies comparing the effectiveness of biologics in the treatment of axial spondyloarthritis (axSpA) are sparse [1]. One study comparing secukinumab and adalimumab biosimilar is ongoing.…
Abstract Number: 0163 • ACR Convergence 2020
Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach
Johan Dalén¹, Karin Luttropp¹, Tor Olofsson², Christopher Black³ and Amy Puenpatom⁴, ¹ICON plc, Stockholm, Sweden, Stockholm, Sweden, ²Department of Clinical Sciences, Lund, Rheumatology, Lund University, Sweden; Department of Rheumatology, Skåne University Hospital, Lund, Sweden, Lund, Sweden, ³Merck & Co., Inc., Kenilworth, NJ, USA, Rahway, NJ, ⁴Merck & Co., Inc., Kenilworth, NJ, USA, North Wales, PA
Background/Purpose: Few studies have explored cost consequences of non-persistence in the treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors (SC-TNFi) in Inflammatory Arthritis (IA; rheumatoid arthritis…
Abstract Number: 0885 • ACR Convergence 2020
Impact of HLA-B27 Status on Clinical Outcomes in Patients with Ankylosing Spondylitis Treated with Secukinumab
Atul Deodhar¹, Philip Mease², Denis Poddubnyy³, Vibeke Strand⁴, Paula Machado⁵, Abhijit Shete⁶, Xiangyi Meng⁵ and Marina Magrey⁷, ¹Oregon Health & Science University, Portland, OR, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁴Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Ankylosing spondylitis (AS) is strongly associated with the genetic marker HLA-B27. In patients with AS, negative HLA-B27 status is a predictor of worse response…
Abstract Number: 1318 • ACR Convergence 2020
Catastrophizing in Patients with Axial Spondyloarthritis and Psoriatic Arthritis
Baptiste Coste¹, Charlotte Traverson¹, Elisabeth Filhol¹, Soraya Benamar¹, Jacques Morel², Sabine Laurent-Chabalier³, Bernard Combe⁴, Claire Daien², Cédric Lukas⁵, Charlotte Hua¹ and Cecile Gaujoux-Viala⁶, ¹Department of Rheumatology, CHU Nîmes, University of Montpellier-Nîmes, France, Nimes, France, ²Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France, ³Department of Biostatistics, Clinical Epidemiology, Public Health and innovation in Methodology, CHU Nîmes, University of Montpellier-Nîmes, France, Nimes, France, ⁴University of Montpellier, Montpellier, France, ⁵CHU Montpellier and University of Montpellier, Montpellier, France, ⁶Department of Rheumatology, CHU Nîmes, University of Montpellier-Nîmes, France, EA2415, University of Montpellier, Montpellier, France, Nîmes, France
Background/Purpose: Catastrophizing is a negative cognitivo-affective response to an anxiety-provoking stimulus, especially to pain. Catastrophism plays a role in maintaining chronic pain and is associated…
Abstract Number: 1411 • ACR Convergence 2020
CD8+ T Cell Subsets and Immune Checkpoint Profiles in Ankylosing Spondylitis Implicate Dysregulation of Cytotoxic T Lymphocytes (CTL)
Michael Tang¹, Zoya Qaiyum², Melissa Lim¹ and Robert Inman², ¹UNIVERSITY HEALTH NETWORK, TORONTO, Canada, ²University Health Network, Toronto, ON, Canada
Background/Purpose: Ankylosing Spondylitis (AS) is characterized by chronic inflammation which underlies the pain and precedes spinal ankylosis. The strongest genetic association with AS is the…
Abstract Number: 1873 • ACR Convergence 2020
The Changing Profile of Ankylosing Spondylitis in the Biologic Era
Lauren Ridley¹, Michael Weisman², Lianne Gensler³, Michael Ward⁴, Mark Hwang⁵, Amirali Tahanan⁶, MinJae Lee⁷, Mohammad Rahbar⁶, Mariko Ishimori⁸, Matthew Brown⁹ and John Reveille¹⁰, ¹McGovern Medical School at UTHealth, Houston, TX, ²Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³University of California San Francisco, San Francisco, CA, ⁴National Institutes of Health, Bethesda, MD, ⁵McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ⁶McGovern Medical School at UTHealth, Houston, ⁷UT Southwestern, Dallas, ⁸Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ¹⁰Department of Internal Medicine, University of Texas, Houston, TX
Background/Purpose: To compare disease characteristics, comorbidities, and medication utilization of 573 patients with ankylosing spondylitis (AS) with short (< 20 years) disease duration (from symptom…
Abstract Number: 1899 • ACR Convergence 2020
Life Expectancy a Swiss Cohort of Patients with Ankylosing Spondylitis: A 35-Year Follow-up Study
Zhixiu Li¹, Mohammad Khan², Sjef van der Linden³, Peter Villiger⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶, Matthew Brown⁷ and Muhammad Khan⁸, ¹Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ²Kent State University, Kent, OH, ³Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ⁴Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁸Case Western Reserve University, Cleveland OH, Westlake, OH
Background/Purpose: To investigate life expectancy of a Swiss cohort of patients with ankylosing spondylitis (AS) versus general population during 35 years of longitudinal follow up,…
Abstract Number: 0165 • ACR Convergence 2020
Work Disability and Predictors of Poor Work Outcome in Patients with Axial Spondyloarthritis
Elif Ediboglu¹, Dilek Solmaz², Hande Ece Oz³, Gokhan Kabadayı⁴, Haluk Cinaklı⁴, Eda Otman Akat³, Mustafa Ozmen⁴ and Servet Akar³, ¹Izmir Katip Celebi University, Izmir, Izmir, Turkey, ²Izmir Katip Celebi University, Department of Internal Medicine, Division of Rheumatology, Izmir, TURKEY, Izmir, Turkey, ³Izmir Katip Celebi University, Izmir, Turkey, ⁴Izmir Katip Celebi University, Izmir
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which may lead substantial functional limitation. The disease more commonly affects men in their third decade…
Abstract Number: 0886 • ACR Convergence 2020
Achievement of Partial Remission and Inactive Disease in Upadacitinib-Treated Patients with Ankylosing Spondylitis
Atul Deodhar¹, Andrew Östör², Anna Maniccia³, Fabiana Ganz⁴, Tianming Gao³, Alvina D. Chu⁵ and Denis Poddubnyy⁶, ¹Oregon Health & Science University, Portland, OR, ²Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Inc., Baar, Switzerland, ⁵AbbVie, North Chicago, IL, ⁶Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Assessment of SpondyloArthritis international Society (ASAS) response criteria and AS Disease Activity Score (ASDAS) are both commonly used, rigorous composite indices consisting of components…
Abstract Number: 1319 • ACR Convergence 2020
Disease Activity and Mental Health of as Patients: A Cross-section Study with Self-assessments Based on Smart System of Disease Management (SSDM) Mobile Tools
Hui Song¹, Hua Wei², Miaojia Zhang³, Lijun Wu⁴, Zhenbiao Wu⁵, Aichun Chu⁶, Bei Wang⁷, Wenqiang Fan⁸, Xiaohan Wang⁹, Xiaoqi Chen¹⁰, Henglian Wu¹¹, Wenyu Zhou¹², Fei Xiao¹³, Hui Xiao¹⁴, Yuhua Jia¹³, Bing Wu¹³ and Jing Lu¹⁵, ¹Beijing Jishuitan Hospital, Beijing, China (People's Republic), ²Northern Jiangsu People's Hospital, Yangzhou, China (People's Republic), ³Jiangsu Province Hospital, The first affiliated hospital of Nanjing medical university, Nanjing, China (People's Republic), ⁴People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China (People's Republic), ⁵The First Affiliated Hospital of The Air Force Medical University, Xi＇an, Shanxi, China (People's Republic), ⁶Remin Hospital of Wuhan University Hubei General Hospital, Wuhan, China (People's Republic), ⁷Beijing Hospital of Traditional Chinese Medicine, Beijing, China (People's Republic), ⁸Central Hospital of XinXiang, Xinxiang, China (People's Republic), ⁹Anyang district hospital, Anyang, Henan, China (People's Republic), ¹⁰Zhongnan Hospital of Wuhan University, Wuhan, China (People's Republic), ¹¹Dongguan Donghua Hospital, Dongguan, Guangdong, China (People's Republic), ¹²Wuhan No. 4 Hospital, Wuhan, China (People's Republic), ¹³Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ¹⁴Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹⁵First Affiliated Hospital of China Medical University, Shenyang, China (People's Republic)
Background/Purpose: WHO survey showed that the prevalence of anxiety and depression in Chinese population and Chinese patients with chronic diseases were between 3.1% - 4.2%…
Abstract Number: 1477 • ACR Convergence 2020
Adherence in Patients with Chronic Rheumatic Diseases Treated with Biological and Synthetic Targeted Therapies During COVID-19 Pandemic
Patricia Castro Pérez¹, Alberto Onteniente González¹, Angel Aragón Díez¹, Angel Gallegos Cid¹, Jesús Garcia-Arroba Muñoz¹ and Jose Manuel Rodriguez heredia¹, ¹Hospital de Getafe, Madrid, Spain
Background/Purpose: Adherence to treatments for chronic rheumatic diseases is influenced by many factors, including the patient's belief in the development of adverse effects such as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].